Terremoto Biosciences raised $108 million in a Series C to advance oral drug candidates targeting AKT, including TER-2013 for solid tumors with specific genetic alterations and TER-4480 for hereditary hemorrhagic telangiectasia (HHT). The funding added investors including RA Capital, Deep Track Capital, Osage University Partners, and BeOne Medicines, with prior backers also participating. The company positions its covalency technologies as a way to deliver improved efficacy and safety versus competing AKT inhibitors, aiming to enter first-in-human testing for TER-2013 in solid tumors and expand clinical efforts for HHT in parallel.